Skip to content

Study on the application of bupivacaine liposome in serratus block before thoracic surgery

Study on the application of bupivacaine liposome in serratus block before thoracic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104564
Enrollment
Unknown
Registered
2025-06-19
Start date
2025-06-20
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic operation

Interventions

Bupivacaine Group:Preoperatively under general anesthesia, an ultrasound-guided serratus plane block was administered on the surgical side with 15 mL of 0.375% (3.75 mg/mL) bupivacaine solution
Liposome Bupivacaine Arm Group:Under general anesthesia preoperatively, ultrasound-guided serratus plane blockade was administered on the surgical side with 7.5 mL of 1.33% (13.3 mg/mL) liposomal bupi

Sponsors

Jinshan Branch of Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.18~85 years old; 2.ASAI.~II. level; 3.BMI:18~28 kg/m^2; 4. Patients who are scheduled to undergo thoracic surgery under general anesthesia; 5. Patients who are able to understand and complete the self-assessment.

Exclusion criteria

Exclusion criteria: 1. Patients with severe underlying diseases of the respiratory system and cardiovascular system; Patients with anticipated difficult airway; 2. Patients with a history of epilepsy, psychiatric diseases and cognitive dysfunction; 3. Patients with hepatic and renal insufficiency; 4. Patients with a history of bupivacaine allergy and other serious drug allergies, drug abuse and drug abuse; 5. Patients with a history of chronic pain and neurological disease in the past; 6. Patients with coagulation dysfunction; 7. Patients with skin infection at the puncture site; 8. Pregnant women; 9. Patients with other systemic malignancies; Patients who underwent other surgeries at the same time.

Design outcomes

Secondary

MeasureTime frame
Analgesic consumption;Time to extubation;First postoperative ambulation time;Total number of ambulation episodes;Postoperative length of stay;Postoperative complications;

Primary

MeasureTime frame
Postoperative pain assessment;Postoperative anesthesia adverse reactions;

Countries

China

Contacts

Public ContactXing Xue

Jinshan Branch of Shanghai Sixth People's Hospital

xuex617@163.com+86 133 2133 5268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026